Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Active Ulcerative Colitis
NCT02289417Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of apremilast in ulcerative colitis (UC), sponsored by Amgen. Started Jan 2015; status: completed.
02
Drugs
apremilast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02289417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289417.